http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Polymorphisms in cancer-related pathway genes and lung cancer
Lee, Shin Yup,Kang, Hyo-Gyoung,Choi, Jin Eun,Jung, Deuk Kju,Lee, Won Kee,Lee, Hyun Chul,Lee, So Yeon,Yoo, Seung Soo,Lee, Jaehee,Seok, Yangki,Lee, Eung Bae,Cha, Seung Ick,Cho, Sukki,Kim, Chang Ho,Lee, European Respiratory Society 2016 The European respiratory journal Vol.48 No.4
<P>We evaluated the associations between potentially functional variants in a comprehensive list of cancer-related genes and lung cancer in a Korean population.</P><P>A total of 1969 potentially functional single nucleotide polymorphisms (SNPs) of 1151 genes involved in carcinogenesis were evaluated using an Affymetrix custom-made GeneChip in 610 nonsmall cell lung cancer patients and 610 healthy controls. A replication study was conducted in an independent set of 490 cases and 486 controls. 68 SNPs were significantly associated with lung cancer in the discovery set and tested for replication.</P><P>Among the 68 SNPs, three SNPs (corepressor interacting with RBPJ 1 (<I>CIR1</I>) rs13009079T>C, ribonucleotide reductase M1 (<I>RRM1</I>) rs1465952T>C and solute carrier family 38, member 4 (<I>SLC38A4</I>) rs2429467C>T) consistantly showed significant associations with lung cancer in the replication study. In combined analysis, adjusted odds ratio for <I>CIR1</I> rs13009079T>C, <I>RRM1</I> rs1465952T>C and <I>SLC38A4</I> rs2429467C>T were 0.69, 0.71 and 0.73, respectively (p=4×10<SUP>−5</SUP>, 0.01 and 0.001, respectively) under the dominant model. The relative mRNA expression level of <I>CIR1</I> was significantly associated with rs13009079T>C genotypes in normal lung tissues (ptrend=0.03).</P><P>These results suggest that the three SNPs, particularly <I>CIR1</I> rs13009079T>C, may play a role in the pathogenesis of lung cancer.</P>
Lee, Jae Yeon,Yoo, Seung Soo,Kang, Hyo-Gyoung,Jin, Guang,Bae, Eun Young,Choi, Yi Young,Choi, Jin Eun,Jeon, Hyo-Sung,Lee, Jaehee,Lee, Shin Yup,Cha, Seung-Ick,Kim, Chang Ho,Park, Jae Yong The Korean Academy of Medical Sciences 2012 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.27 No.12
<P>A genome-wide association study has identified the 15q25 region as being associated with the risk of chronic obstructive pulmonary disease (COPD) in Caucasians. This study intended as a confirmatory assessment of this association in a Korean population. The rs6495309C > T polymorphism in the promoter of nicotinic acetylcholine receptor alpha subunit 3 (<I>CHRNA3</I>) gene was investigated in a case-control study that consisted of 406 patients with COPD and 394 healthy control subjects. The rs6495309 CT or TT genotype was associated with a significantly decreased risk of COPD when compared to the rs6495309 CC genotype (adjusted odds ratio = 0.69, 95% confidence interval = 0.50-0.95, <I>P</I> = 0.023). The effect of the rs6495309C > T on the risk of COPD was more evident in moderate to very severe COPD than in mild COPD under a dominant model for the variant T allele (<I>P</I> = 0.024 for homogeneity). The <I>CHRNA3</I> rs6495309C > T polymorphism on chromosome 15q25 is associated with the risk of COPD in a Korean population.</P>
Clinical relevance of syncope in patients with pulmonary embolism
Lee, Yong-Hoon,Cha, Seung-Ick,Shin, Kyung-Min,Lim, Jae-Kwang,Yoo, Seung-Soo,Lee, Shin-Yup,Lee, Jaehee,Kim, Chang-Ho,Park, Jae-Yong,Lee, Won Kee Elsevier 2018 Thrombosis research Vol.164 No.-
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Syncope is an unusual clinical manifestation of pulmonary embolism (PE), and the clinical significance of syncope in PE patients remains controversial. We investigated the incidence of syncope, examined the clinical factors associated with syncope, and assessed the association between syncope and the short-term outcomes of PE.</P> <P><B>Methods</B></P> <P>We retrospectively classified patients presenting with PE into 2 groups: patients with syncope and those without syncope. We compared the clinical and computed tomography parameters between the groups.</P> <P><B>Results</B></P> <P>Among 1084 patients diagnosed with PE, 45 (4.2%) presented with syncope. Four patients which presented with cardiac arrest were excluded from the study. The syncope group showed significantly higher blood biomarker levels and higher rates of central PE and right ventricular dilation than the control group. Unprovoked PE (odds ratio [OR] 8.046, 95% confidence interval [CI] 3.073–21.069, p < 0.001), female sex (OR 3.419, 95% CI 1.348–8.675, p = 0.010), central PE (OR 2.854, 95% CI 1.298–6.278, p = 0.009), and troponin I level (OR 2.812, 95% CI 1.765–4.480, p < 0.001) were observed to be independent factors associated with syncope in PE patients. However, multivariate analysis showed that the presence of syncope was not a significant predictor of adverse outcomes and recurrent venous thromboembolism in PE patients.</P> <P><B>Conclusions</B></P> <P>Although syncope is associated with a more severe form of PE, it does not influence the short-term prognosis of PE. Central PE, blood troponin I level, unprovoked PE, and female sex were observed to be clinical factors related with syncope in patients with PE.</P> <P><B>Highlights</B></P> <P> <UL> <LI> The clinical implications of syncope in patients with pulmonary embolism are suggested. </LI> <LI> Syncope was associated with a more severe form of pulmonary embolism. </LI> <LI> Syncope did not influence the short-term prognosis of pulmonary embolism. </LI> <LI> Central emboli and blood troponin I level were independent factors of syncope. </LI> <LI> Unprovoked pulmonary embolism and female sex were also associated with syncope. </LI> </UL> </P>
Lee, Jaehee,Lim, Jae Kwang,Kim, Eun Jin,Lee, Deok Heon,Kim, Yu Kyung,Yoo, Seung Soo,Lee, Shin Yup,Cha, Seung Ick,Park, Jae Yong,Kim, Chang Ho AME Publishing Company 2018 Journal of thoracic disease Vol.10 No.5
<P>Conclusions: The present study suggests that treatment completion, the cause of death, and risk factors for TB-related deaths may be different according to age groups in adult patients with miliary TB.</P>
Jaehee Lee,Sung-Kwan Joo IEEE 2013 IEEE transactions on applied superconductivity Vol.23 No.3
<P>An increase in the generation capacity can lead to an increase in the fault current levels in a power system. The increased fault currents can then impose additional operation costs in power system operation. When new generators are installed, the appropriate use of a superconducting fault current limiter (SFCL) not only reduces the maximum fault current but also improves the efficiency of power system operation. Therefore, there is an increasing need to evaluate the economics of an SFCL by considering the operation costs of a power system and the investment costs of an SFCL. In this paper, a systematic method to assess the economic benefits of an SFCL as an alternative to the bus-splitting method is proposed. Numerical results are presented to illustrate the effectiveness of the proposed SFCL economic assessment method.</P>
Lee, Jaehee,Lim, Jae Kwang,Lee, So Yeon,Yoo, Seung Soo,Lee, Shin Yup,Cha, Seung Ick,Park, Jae Yong,Kim, Chang Ho Elsevier 2016 The American journal of the medical sciences Vol.351 No.2
<P>Objectives: Tuberculous pleural effusion (TPE) is generally characterized by lymphocytic exudative effusion, either free flowing or loculated. However, patients can also have neutrophilic loculated TPE, although little data are available concerning the incidence and characteristics of this form of TPE. It is important to differentiate between neutrophilic loculated TPE and complicated parapneumonic effusion (PPE), which also shows neutrophilic loculated effusion but needs a different management approach. The present study evaluated the incidence and characteristics of neutrophilic loculated TPE and differentiated it from complicated PPE. Materials and Methods: Between 2009 and 2014, a cohort of patients with TPE was retrospectively reviewed in a South Korean referral hospital. Clinical, laboratory, computed tomography and pleural fluid findings of patients with neutrophilic loculated TPE were compared to those of patients with neutrophilic free-flowing TPE and complicated PPE, respectively. Results: Neutrophilic TPE was observed in 33 (10%) out of 344 patients with TPE. Of these, 10 (30%) patients exhibited loculation of the pleural fluid. These patients showed distinct pleural fluid characteristics. The classical pleural fluid biomarker levels were more intense than those observed in 23 patients with neutrophilic free-flowing TPE, but similar to those of 54 patients with complicated PPE. A high mycobacterial burden was observed in the pleural fluid, and favorable outcomes were achieved with antituberculosis drug administration alone. Nodular parenchymal lesions and pleural fluid adenosine deaminase levels were independent discriminators of neutrophilic loculated TPE and PPE. Conclusions: These results may be helpful to understand and manage patients with neutrophilic loculated TPE and differentiate them from patients with complicated PPE.</P>
( Jaehee Lee ),( Deok Heon Lee ),( Ji Eun Park ),( Yong Hoon Lee ),( Sun Ha Choi ),( Hyewon Seo ),( Seung Soo Yoo ),( Shin Yup Lee ),( Seung-ick Cha ),( Jae Yong Park ),( Chang Ho Kim ) 대한내과학회 2024 The Korean Journal of Internal Medicine Vol.39 No.2
Background/Aims: Epidermal growth factor receptor (EGFR) mutation is important in determining the treatment strategy for advanced lung cancer patients with malignant pleural effusion (MPE). Contrary to serum carcinoembryonic antigen (S-CEA) levels, the associations between pleural fluid CEA (PF-CEA) levels and EGFR mutation status as well as between PF-CEA levels and treatment efficacy have rarely been investigated in lung adenocarcinoma patients with MPE. Methods: This retrospective study enrolled lung adenocarcinoma patients with MPE and available PF-CEA levels and EGFR mutation results. The patients were categorized based on PF-CEA levels: < 10 ng/mL, 10-100 ng/mL, 100-500 ng/mL, and ≥ 500 ng/mL. The association between PF-CEA levels and EGFR mutation status as well as their therapeutic impact on overall survival was compared among the four groups. Results: This study included 188 patients. PF-CEA level was found to be an independent predictor of EGFR mutation but not S-CEA level. The EGFR mutation rates were higher as the PF-CEA levels increased, regardless of cytology results or sample types. Among EGFR-mutant lung adenocarcinoma patients receiving EGFR-tyrosine kinase inhibitor (TKI) treatment, those with high PF-CEA levels had significantly better survival outcomes than those with low PF-CEA levels. Conclusion: High PF-CEA levels were associated with high EGFR mutation rate and may lead to a favorable clinical outcome of EGFR-TKI treatment in EGFR-mutant lung adenocarcinoma patients with MPE. These findings highlight the importance of actively investigating EGFR mutation detection in patients with suspected MPE and elevated PF-CEA levels despite negative cytology results.
( Jaehee Mun ),( Seokyung Kim ),( Eun Ji Lee ),( Soo Jin Park ),( Joo-hyuk Son ),( Maria Lee ),( Tae-wook Kong ),( Hee Seung Kim ),( Jiheum Paek ),( Hyun Hoon Chung ),( Suk-joon Chang ),( Jae Weon Kim 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: Cremophor-free polymeric micelle formulation of paclitaxel (Genexol-PM) plus carboplatin (PM/C) has been reported to have a non-inferior effect with tolerable toxicities when compared to the standard paclitaxel plus carboplatin (P/C) in ovarian cancer. However, there is still a lack of evidence on the effect of an increased dose of paclitaxel in PM/C, especially, when compared to P/C and paclitaxel plus carboplatin with bevacizumab (P/C/B) in advanced high-grade serous ovarian cancer (HGSO). Thus, we performed a prospective cohort study on PM/C and compared the effect of PM/C with historical control of P/C and P/C/B in HGSO. Methods: We performed a prospective cohort study between October 2015 and June 2019. Patients aged 20 or more years with FIGO stage III-IV HGSO who received PM (260 mg/m<sup>2</sup>)/C (AUC 5) after primary debulking surgery (PDS) were enrolled. We collected clinico-pathologic data from a retrospective cohort when P (175 mg/m<sup>2</sup>)/C (AUC 5) or P (175 mg/m<sup>2</sup>)/C (AUC 5)/B (15 mg/kg) were used as adjuvant treatment after PDS during the same period. Results: A total of 104 patients were enrolled, and 17, 28, and 59 received P/C, P/C/B and, PM/C respectively (Table 1). Complete response was significantly highest in PM/C (29.4 vs. 39.3 vs. 61%, P=0.030; Table 1). Progression-free survival was longest in PM/C (Figure 1) and multivariate analysis showed that gross residual tumor after PDS and P/C were poor prognostic factors (adjusted hazard ratios, 2.415 and 2.751; 95% confidence intervals, 1.172-4.976 and 1.214-6.236; Table 2). Even after adjustment of the patient pool to those with no gross residual tumor after PDS, multivariate analysis still showed that P/C lowered the survival curve (adjusted hazard ratio, 3.342; 95% confidence interval, 1.143-9.777; Table 2). Conclusion: This interim analysis showed that PM/C had a comparable effect to P/C/B for stage III-IV HGSO patients who received optimal cytoreduction during PDS.